The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.

Researchers sought to determine whether modakafusp alfa would be effective in relapsed/refractory multiple myeloma.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

You look at survival for patients with multiple myeloma about 20, 25 years back, it was probably measured, survival was measured, in three to five years, that's the median life expectancy for ...

Kyphoplasty is being used to treat painful osteolytic or fractured vertebrae, but will it become a key treatment option for patients with vertebral osteolyses from multiple myeloma?